Clinical Trial: A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020884) titled 'A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity' on June 06.

Brief Summary: This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.

Study Start Date: Aug. 14, 2024

Study Type: INTERVENTIONAL

Condition: Overweight or Obesity

Intervention: DRUG: ZT002 Injection

Administered SC

DRUG: ZT002 Placebo

Administered SC

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

Disclaimer: Curated by HT Syndication....